Immune targets and neoantigens for cancer immunotherapy and precision medicine
Harnessing the immune system to eradicate malignant cells is becoming a most powerful new approach to cancer therapy. FDA approval of the immunotherapy-based drugs, sipuleucel-T （Provenge）, ipilimumab （Yervoy, anti-CT- LA-4）, and more recently, the programmed cell death （PD）-I antibody （pembroliznma...
Gespeichert in:
| Veröffentlicht in: | Cell research 2017-01, Vol.27 (1), p.11-37 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 37 |
|---|---|
| container_issue | 1 |
| container_start_page | 11 |
| container_title | Cell research |
| container_volume | 27 |
| creator | Wang, Rong-Fu Wang, Helen Y |
| description | Harnessing the immune system to eradicate malignant cells is becoming a most powerful new approach to cancer therapy. FDA approval of the immunotherapy-based drugs, sipuleucel-T （Provenge）, ipilimumab （Yervoy, anti-CT- LA-4）, and more recently, the programmed cell death （PD）-I antibody （pembroliznmab, Keytruda）, for the treatment of multiple types of cancer has greatly advanced research and clinical studies in the field of cancer immunotherapy. Furthermore, recent clinical trials, using NY-ESO-l-specific T cell receptor （TCR） or CD19-chimeric antigen re- ceptor （CAR）, have shown promising clinical results for patients with metastatic cancer. Current success of cancer immunotherapy is built upon the work of cancer antigens and co-inhibitory signaling molecules identified 20 years ago. Among the large numbers of target antigens, CD19 is the best target for CAR T cell therapy for blood cancer, but CAR-engineered T cell immunotherapy does not yet work in solid cancer. NY-ESO-1 is one of the best targets for TCR-based immunotherapy in solid cancer. Despite the great success of checkpoint blockade therapy, more than 50% of cancer patients fail to respond to blockade therapy. The advent of new technologies such as next-generation sequencing has enhanced our ability to search for new immune targets in onco-immunology and accelerated the de- velopment of immunotherapy with potentially broader coverage of cancer patients. In this review, we will discuss the recent progresses of cancer immunotherapy and novel strategies in the identification of new immune targets and mu- tation-derived antigens （neoantigens） for cancer immunotherapy and immunoprecision medicine. |
| doi_str_mv | 10.1038/cr.2016.155 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5223235</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cqvip_id>671249560</cqvip_id><sourcerecordid>1859485265</sourcerecordid><originalsourceid>FETCH-LOGICAL-c506t-2286b74c1ebab1b4992fd219e2c738ce885f1a48ec83a72081809e7ff86e28943</originalsourceid><addsrcrecordid>eNqNkU1v1DAQhiMEoqVw4o4iuCCVLP6MxxckVFGoVMEFzpbjnWRdbeytnSD13-N0l1VBHDh5pHn8jMdvVb2kZEUJh_curRih7YpK-ag6pUpAo4DD41ITQhvSEnZSPcv5hhAmhaRPqxMGpdQKTquvV-M4B6wnmwaccm3Dug4YbZj8gCHXfUy1s8Fhqv1CxmmDye7u7sFdQuezj6Eece2dD_i8etLbbcYXh_Os-nH56fvFl-b62-eri4_XjZOknRrGoO2UcBQ729FOaM36NaMamVMcHALInloB6IBbxQhQIBpV30OLDLTgZ9WHvXc3d2W2wzAluzW75Eeb7ky03vzZCX5jhvjTSMY447II3h4EKd7OmCcz-uxwu7Vl-zkbClILkKz9L5RzAVTRgr75C72JcwrlJxZKKq2EXITne8qlmHPC_vhuSswSqXHJLJEaek-_erjqkf2dYQHe7YFcWmHA9GDoP32vD9M3MQy35cZR2SrKhJYt4b8ABRm2KA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1855797455</pqid></control><display><type>article</type><title>Immune targets and neoantigens for cancer immunotherapy and precision medicine</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Wang, Rong-Fu ; Wang, Helen Y</creator><creatorcontrib>Wang, Rong-Fu ; Wang, Helen Y</creatorcontrib><description>Harnessing the immune system to eradicate malignant cells is becoming a most powerful new approach to cancer therapy. FDA approval of the immunotherapy-based drugs, sipuleucel-T （Provenge）, ipilimumab （Yervoy, anti-CT- LA-4）, and more recently, the programmed cell death （PD）-I antibody （pembroliznmab, Keytruda）, for the treatment of multiple types of cancer has greatly advanced research and clinical studies in the field of cancer immunotherapy. Furthermore, recent clinical trials, using NY-ESO-l-specific T cell receptor （TCR） or CD19-chimeric antigen re- ceptor （CAR）, have shown promising clinical results for patients with metastatic cancer. Current success of cancer immunotherapy is built upon the work of cancer antigens and co-inhibitory signaling molecules identified 20 years ago. Among the large numbers of target antigens, CD19 is the best target for CAR T cell therapy for blood cancer, but CAR-engineered T cell immunotherapy does not yet work in solid cancer. NY-ESO-1 is one of the best targets for TCR-based immunotherapy in solid cancer. Despite the great success of checkpoint blockade therapy, more than 50% of cancer patients fail to respond to blockade therapy. The advent of new technologies such as next-generation sequencing has enhanced our ability to search for new immune targets in onco-immunology and accelerated the de- velopment of immunotherapy with potentially broader coverage of cancer patients. In this review, we will discuss the recent progresses of cancer immunotherapy and novel strategies in the identification of new immune targets and mu- tation-derived antigens （neoantigens） for cancer immunotherapy and immunoprecision medicine.</description><identifier>ISSN: 1001-0602</identifier><identifier>ISSN: 1748-7838</identifier><identifier>EISSN: 1748-7838</identifier><identifier>DOI: 10.1038/cr.2016.155</identifier><identifier>PMID: 28025978</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/250/1933 ; 631/250/2152/1566/20 ; 631/250/516 ; 692/699/67/1059/2325 ; Amino Acid Sequence ; Antigens, Neoplasm - metabolism ; Biomedical and Life Sciences ; Cancer Vaccines - immunology ; Cell Biology ; Humans ; Immune system ; Immunology ; Immunotherapy ; Life Sciences ; Lymphocyte Activation - immunology ; Neoplasms - immunology ; Neoplasms - therapy ; Precision Medicine ; Review ; T细胞受体 ; 免疫指标 ; 免疫治疗 ; 治疗药物 ; 癌症治疗 ; 程序性细胞死亡 ; 肿瘤免疫 ; 靶抗原</subject><ispartof>Cell research, 2017-01, Vol.27 (1), p.11-37</ispartof><rights>Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences 2017</rights><rights>Copyright Nature Publishing Group Jan 2017</rights><rights>Copyright © 2017 Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences 2017 Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c506t-2286b74c1ebab1b4992fd219e2c738ce885f1a48ec83a72081809e7ff86e28943</citedby><cites>FETCH-LOGICAL-c506t-2286b74c1ebab1b4992fd219e2c738ce885f1a48ec83a72081809e7ff86e28943</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://image.cqvip.com/vip1000/qk/85240X/85240X.jpg</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223235/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223235/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,41487,42556,51318,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28025978$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Rong-Fu</creatorcontrib><creatorcontrib>Wang, Helen Y</creatorcontrib><title>Immune targets and neoantigens for cancer immunotherapy and precision medicine</title><title>Cell research</title><addtitle>Cell Res</addtitle><addtitle>Cell Research</addtitle><description>Harnessing the immune system to eradicate malignant cells is becoming a most powerful new approach to cancer therapy. FDA approval of the immunotherapy-based drugs, sipuleucel-T （Provenge）, ipilimumab （Yervoy, anti-CT- LA-4）, and more recently, the programmed cell death （PD）-I antibody （pembroliznmab, Keytruda）, for the treatment of multiple types of cancer has greatly advanced research and clinical studies in the field of cancer immunotherapy. Furthermore, recent clinical trials, using NY-ESO-l-specific T cell receptor （TCR） or CD19-chimeric antigen re- ceptor （CAR）, have shown promising clinical results for patients with metastatic cancer. Current success of cancer immunotherapy is built upon the work of cancer antigens and co-inhibitory signaling molecules identified 20 years ago. Among the large numbers of target antigens, CD19 is the best target for CAR T cell therapy for blood cancer, but CAR-engineered T cell immunotherapy does not yet work in solid cancer. NY-ESO-1 is one of the best targets for TCR-based immunotherapy in solid cancer. Despite the great success of checkpoint blockade therapy, more than 50% of cancer patients fail to respond to blockade therapy. The advent of new technologies such as next-generation sequencing has enhanced our ability to search for new immune targets in onco-immunology and accelerated the de- velopment of immunotherapy with potentially broader coverage of cancer patients. In this review, we will discuss the recent progresses of cancer immunotherapy and novel strategies in the identification of new immune targets and mu- tation-derived antigens （neoantigens） for cancer immunotherapy and immunoprecision medicine.</description><subject>631/250/1933</subject><subject>631/250/2152/1566/20</subject><subject>631/250/516</subject><subject>692/699/67/1059/2325</subject><subject>Amino Acid Sequence</subject><subject>Antigens, Neoplasm - metabolism</subject><subject>Biomedical and Life Sciences</subject><subject>Cancer Vaccines - immunology</subject><subject>Cell Biology</subject><subject>Humans</subject><subject>Immune system</subject><subject>Immunology</subject><subject>Immunotherapy</subject><subject>Life Sciences</subject><subject>Lymphocyte Activation - immunology</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - therapy</subject><subject>Precision Medicine</subject><subject>Review</subject><subject>T细胞受体</subject><subject>免疫指标</subject><subject>免疫治疗</subject><subject>治疗药物</subject><subject>癌症治疗</subject><subject>程序性细胞死亡</subject><subject>肿瘤免疫</subject><subject>靶抗原</subject><issn>1001-0602</issn><issn>1748-7838</issn><issn>1748-7838</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNkU1v1DAQhiMEoqVw4o4iuCCVLP6MxxckVFGoVMEFzpbjnWRdbeytnSD13-N0l1VBHDh5pHn8jMdvVb2kZEUJh_curRih7YpK-ag6pUpAo4DD41ITQhvSEnZSPcv5hhAmhaRPqxMGpdQKTquvV-M4B6wnmwaccm3Dug4YbZj8gCHXfUy1s8Fhqv1CxmmDye7u7sFdQuezj6Eece2dD_i8etLbbcYXh_Os-nH56fvFl-b62-eri4_XjZOknRrGoO2UcBQ729FOaM36NaMamVMcHALInloB6IBbxQhQIBpV30OLDLTgZ9WHvXc3d2W2wzAluzW75Eeb7ky03vzZCX5jhvjTSMY447II3h4EKd7OmCcz-uxwu7Vl-zkbClILkKz9L5RzAVTRgr75C72JcwrlJxZKKq2EXITne8qlmHPC_vhuSswSqXHJLJEaek-_erjqkf2dYQHe7YFcWmHA9GDoP32vD9M3MQy35cZR2SrKhJYt4b8ABRm2KA</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Wang, Rong-Fu</creator><creator>Wang, Helen Y</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>2RA</scope><scope>92L</scope><scope>CQIGP</scope><scope>W94</scope><scope>WU4</scope><scope>~WA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170101</creationdate><title>Immune targets and neoantigens for cancer immunotherapy and precision medicine</title><author>Wang, Rong-Fu ; Wang, Helen Y</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c506t-2286b74c1ebab1b4992fd219e2c738ce885f1a48ec83a72081809e7ff86e28943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>631/250/1933</topic><topic>631/250/2152/1566/20</topic><topic>631/250/516</topic><topic>692/699/67/1059/2325</topic><topic>Amino Acid Sequence</topic><topic>Antigens, Neoplasm - metabolism</topic><topic>Biomedical and Life Sciences</topic><topic>Cancer Vaccines - immunology</topic><topic>Cell Biology</topic><topic>Humans</topic><topic>Immune system</topic><topic>Immunology</topic><topic>Immunotherapy</topic><topic>Life Sciences</topic><topic>Lymphocyte Activation - immunology</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - therapy</topic><topic>Precision Medicine</topic><topic>Review</topic><topic>T细胞受体</topic><topic>免疫指标</topic><topic>免疫治疗</topic><topic>治疗药物</topic><topic>癌症治疗</topic><topic>程序性细胞死亡</topic><topic>肿瘤免疫</topic><topic>靶抗原</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Rong-Fu</creatorcontrib><creatorcontrib>Wang, Helen Y</creatorcontrib><collection>中文科技期刊数据库</collection><collection>中文科技期刊数据库-CALIS站点</collection><collection>中文科技期刊数据库-7.0平台</collection><collection>中文科技期刊数据库-自然科学</collection><collection>中文科技期刊数据库-自然科学-生物科学</collection><collection>中文科技期刊数据库- 镜像站点</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cell research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Rong-Fu</au><au>Wang, Helen Y</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immune targets and neoantigens for cancer immunotherapy and precision medicine</atitle><jtitle>Cell research</jtitle><stitle>Cell Res</stitle><addtitle>Cell Research</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>27</volume><issue>1</issue><spage>11</spage><epage>37</epage><pages>11-37</pages><issn>1001-0602</issn><issn>1748-7838</issn><eissn>1748-7838</eissn><abstract>Harnessing the immune system to eradicate malignant cells is becoming a most powerful new approach to cancer therapy. FDA approval of the immunotherapy-based drugs, sipuleucel-T （Provenge）, ipilimumab （Yervoy, anti-CT- LA-4）, and more recently, the programmed cell death （PD）-I antibody （pembroliznmab, Keytruda）, for the treatment of multiple types of cancer has greatly advanced research and clinical studies in the field of cancer immunotherapy. Furthermore, recent clinical trials, using NY-ESO-l-specific T cell receptor （TCR） or CD19-chimeric antigen re- ceptor （CAR）, have shown promising clinical results for patients with metastatic cancer. Current success of cancer immunotherapy is built upon the work of cancer antigens and co-inhibitory signaling molecules identified 20 years ago. Among the large numbers of target antigens, CD19 is the best target for CAR T cell therapy for blood cancer, but CAR-engineered T cell immunotherapy does not yet work in solid cancer. NY-ESO-1 is one of the best targets for TCR-based immunotherapy in solid cancer. Despite the great success of checkpoint blockade therapy, more than 50% of cancer patients fail to respond to blockade therapy. The advent of new technologies such as next-generation sequencing has enhanced our ability to search for new immune targets in onco-immunology and accelerated the de- velopment of immunotherapy with potentially broader coverage of cancer patients. In this review, we will discuss the recent progresses of cancer immunotherapy and novel strategies in the identification of new immune targets and mu- tation-derived antigens （neoantigens） for cancer immunotherapy and immunoprecision medicine.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>28025978</pmid><doi>10.1038/cr.2016.155</doi><tpages>27</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1001-0602 |
| ispartof | Cell research, 2017-01, Vol.27 (1), p.11-37 |
| issn | 1001-0602 1748-7838 1748-7838 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5223235 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; SpringerLink Journals - AutoHoldings |
| subjects | 631/250/1933 631/250/2152/1566/20 631/250/516 692/699/67/1059/2325 Amino Acid Sequence Antigens, Neoplasm - metabolism Biomedical and Life Sciences Cancer Vaccines - immunology Cell Biology Humans Immune system Immunology Immunotherapy Life Sciences Lymphocyte Activation - immunology Neoplasms - immunology Neoplasms - therapy Precision Medicine Review T细胞受体 免疫指标 免疫治疗 治疗药物 癌症治疗 程序性细胞死亡 肿瘤免疫 靶抗原 |
| title | Immune targets and neoantigens for cancer immunotherapy and precision medicine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T15%3A00%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immune%20targets%20and%20neoantigens%20for%20cancer%20immunotherapy%20and%20precision%20medicine&rft.jtitle=Cell%20research&rft.au=Wang,%20Rong-Fu&rft.date=2017-01-01&rft.volume=27&rft.issue=1&rft.spage=11&rft.epage=37&rft.pages=11-37&rft.issn=1001-0602&rft.eissn=1748-7838&rft_id=info:doi/10.1038/cr.2016.155&rft_dat=%3Cproquest_pubme%3E1859485265%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1855797455&rft_id=info:pmid/28025978&rft_cqvip_id=671249560&rfr_iscdi=true |